Lactose (India)

Who are in the management team of Lactose (India)?

As of March 2023, the management team of Lactose (India) includes Atul Maheshwari (Chairman & Managing Director), S M Maheshwari (Whole Time Director & CFO), and independent directors Pramod Kalani, G K Sarda, and Dhaval J Soni.

As of March 2023, the management team of Lactose (India) includes:<BR><BR>1. Atul Maheshwari - Chairman & Managing Director<BR>2. S M Maheshwari - Whole Time Director & CFO<BR>3. Pramod Kalani - Independent Non-Executive Director<BR>4. G K Sarda - Independent Non-Executive Director<BR>5. Dhaval J Soni - Independent Non-Executive Director<BR><BR>These individuals play key roles in the governance and management of the company.

What does Lactose (India) do?

Lactose (India) Ltd manufactures and trades edible and pharmaceutical grade lactose within the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of 28 Cr and a net profit of 1 Cr, with a market cap of Rs 132 Cr.

Overview: <BR>Lactose (India) Ltd is engaged in the manufacturing and trading of pharmaceutical products, specifically edible and pharmaceutical grade lactose, and operates within the Pharmaceuticals & Biotechnology industry as a micro-cap company.<BR><BR>History: <BR>Lactose (India) Ltd was incorporated in March 1991 as a Public Limited Company. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 28 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 132 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 26.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.83 <BR>Return on Equity: 10.04% <BR>Price to Book: 2.56 <BR><BR>Contact Details: <BR>Address: Survey No 6, Village Poicha (Rania) Savli Vadodara Gujarat : 391780 <BR>Tel: 91-02667-244308/244729 <BR>Email: investor.lactose@gmail.com <BR>Website: http://www.lactoseindia.com

Has Lactose (India) declared dividend?

No Dividend History Available

Who are the peers of the Lactose (India)?

Lactose (India) peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Parnax Lab, Mangalam Drugs, Welcure Drugs, and Samrat Pharma. Lactose (India) has below average management risk, growth, and capital structure compared to its peers, with a 1-year return of -35.55%.

Peers: The peers of Lactose (India) are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Parnax Lab, Mangalam Drugs, Welcure Drugs, and Samrat Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Torrent Pharma, Dr Reddy's Labs, and Samrat Pharma, while Good management risk is found at Divi's Lab. Below Average management risk is noted for Lactose (India), Parnax Lab, Welcure Drugs, and Mangalam Drugs. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Lactose (India), Torrent Pharma, and Mangalam Drugs. Good growth is reported for Parnax Lab, while Average growth is noted for Welcure Drugs and the rest. Capital Structure is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Parnax Lab, while Good capital structure is found at Torrent Pharma. Below Average capital structure is observed for Lactose (India), Mangalam Drugs, and Welcure Drugs.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Lactose (India) has the lowest at -35.55%. Lactose's return is significantly lower than its peers. Additionally, the six-month return is negative for Lactose (India), Sun Pharma.Inds., Torrent Pharma, Dr Reddy's Labs, Parnax Lab, Mangalam Drugs, and Samrat Pharma.

Is Lactose (India) overvalued or undervalued?

As of March 17, 2025, Lactose (India) is considered undervalued with a PE ratio of 25.80 and strong financial metrics, despite a year-to-date stock return of -54.84%, making it an attractive investment compared to peers like Sun Pharma and Cipla.

As of 17 March 2025, Lactose (India) has moved from a fair to an attractive valuation grade, indicating a shift in market perception. The company is currently considered undervalued, supported by a PE ratio of 25.80, an EV to EBITDA of 10.37, and a ROCE of 18.05%. In comparison to its peers, Lactose's valuation metrics stand out; for instance, Sun Pharma has a significantly higher PE ratio of 35.25, while Cipla, another attractive peer, has a PE of 22.99.<BR><BR>Despite recent underperformance, with a year-to-date stock return of -54.84% compared to the Sensex's 5.58%, Lactose (India) presents a compelling investment opportunity given its favorable ratios and the attractive valuation relative to peers like Dr. Reddy's Labs (PE of 19.49) and Zydus Lifesciences (PE of 20.61). This suggests that the market may not fully appreciate Lactose's potential, reinforcing the conclusion that it is undervalued.

What is the technical trend for Lactose (India)?

As of May 26, 2025, Lactose (India) shows a mildly bearish technical trend, with bearish signals from Bollinger Bands and moving averages, despite some mildly bullish indicators in the weekly MACD and KST.

As of 26 May 2025, the technical trend for Lactose (India) has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows a mildly bearish trend. The Bollinger Bands are bearish on both weekly and monthly time frames, and daily moving averages are also bearish. The KST presents a mildly bullish signal on the weekly chart but is mildly bearish on the monthly. Dow Theory reflects a mildly bearish outlook on the weekly and a bullish stance on the monthly. Overall, the current technical stance is mildly bearish, influenced by the bearish signals from Bollinger Bands and moving averages, despite some mildly bullish indicators in the MACD and KST on the weekly time frame.

Who are the top shareholders of the Lactose (India)?

The top shareholders of Lactose (India) include Sangita Maheshwari, who holds 30.73%, and Madhusha Holdings Private Limited, the largest public shareholder at 3.97%. Individual investors collectively own 38.31%, with no mutual funds or foreign institutional investors currently involved.

The top shareholders of Lactose (India) include the promoters, who hold a significant majority of the shares. The promoter with the highest holding is Sangita Maheshwari, owning 30.73% of the company. Additionally, Madhusha Holdings Private Limited is the highest public shareholder, holding 3.97%. Individual investors collectively hold 38.31% of the shares, while there are currently no mutual funds or foreign institutional investors (FIIs) involved in the company.

How big is Lactose (India)?

As of 24th July, Lactose (India) Ltd has a market capitalization of 141.00 Cr, with net sales of 116.40 Cr and a net profit of 5.16 Cr in the latest four quarters. The company reported shareholder's funds of 47.10 Cr and total assets of 100.74 Cr for the annual period ending in March 2024.

As of 24th July, Lactose (India) Ltd has a market capitalization of 141.00 Cr, classifying it as a Micro Cap company.<BR><BR>In the latest four quarters, Lactose (India) reported net sales of 116.40 Cr and a net profit of 5.16 Cr.<BR><BR>For the latest annual period ending in March 2024, the company had shareholder's funds amounting to 47.10 Cr and total assets of 100.74 Cr.

When is the next results date for Lactose (India)?

Lactose (India) is scheduled to announce its results on 13 August 2025.

Lactose (India) is scheduled to declare its results on 13 August 2025.

Are Lactose (India) latest results good or bad?

Lactose (India) reported strong net sales growth of 36% and a 37.5% increase in profit before tax for the quarter ending June 2025. However, a 54.18% decline in profit after tax and rising interest expenses indicate challenges, making the overall results mixed.

Lactose (India) has shown a mixed performance in its latest financial results for the quarter ending June 2025. On the positive side, the company reported net sales of Rs 39.58 crore, which is the highest in the last five quarters and represents a significant growth of 36.0% compared to the previous average. Additionally, profit before tax (PBT) increased by 37.5% over the prior four quarters, reaching Rs 1.88 crore.<BR><BR>However, there are notable challenges as well. The profit after tax (PAT) for the latest six months declined by 54.18% year on year, which is concerning. Furthermore, interest expenses have risen to Rs 4.70 crore, indicating increased borrowing costs.<BR><BR>Overall, while there are encouraging signs in terms of sales and PBT growth, the significant drop in PAT and rising interest expenses suggest that the company's financial health is under pressure. Therefore, the results can be viewed as somewhat mixed, with both positive and negative aspects to consider.

How has been the historical performance of Lactose (India)?

Lactose (India) has experienced significant growth, with net sales increasing from INR 34.96 crore in March 2021 to INR 116.40 crore in March 2025, and profit before tax improving from a loss of INR 3.27 crore to a profit of INR 6.92 crore in the same period. Total liabilities rose to INR 133.47 crore, while cash flow from operating activities showed a positive inflow of INR 2.00 crore in March 2025.

Answer:<BR>The historical performance of Lactose (India) shows a significant growth trajectory in net sales and profitability over the years, with net sales increasing from INR 34.96 crore in March 2021 to INR 116.40 crore in March 2025. The total operating income has mirrored this growth, reaching INR 116.40 crore in March 2025, up from INR 34.96 crore in March 2021. The operating profit (PBDIT) has also seen fluctuations, peaking at INR 20.13 crore in March 2024 before slightly declining to INR 18.41 crore in March 2025. Profit before tax has improved from a loss of INR 3.27 crore in March 2021 to a profit of INR 6.92 crore in March 2025, while profit after tax followed a similar trend, rising from a loss of INR 2.48 crore in March 2021 to INR 5.16 crore in March 2025. <BR><BR>In terms of expenses, raw material costs have increased significantly, reaching INR 60.51 crore in March 2025, which reflects the rising operational scale. The company’s total liabilities have grown from INR 84.00 crore in March 2020 to INR 133.47 crore in March 2025, indicating increased borrowing, particularly in short-term borrowings, which rose to INR 30.31 crore in March 2025. Total assets have also increased, reaching INR 133.47 crore in March 2025, supported by a rise in current assets, particularly inventories and sundry debtors. Cash flow from operating activities has remained stable, with a notable cash inflow of INR 2.00 crore in March 2025, compared to a net outflow in previous years. Overall, Lactose (India) has demonstrated resilience and growth in its financial performance over the past several years.<BR><BR>Breakdown:<BR>Lactose (India) has shown a robust growth pattern in its financial metrics over the years. Net sales surged from INR 34.96 crore in March 2021 to INR 116.40 crore in March 2025, reflecting a strong upward trend. Total operating income followed suit, reaching INR 116.40 crore in March 2025. Operating profit (PBDIT) peaked at INR 20.13 crore in March 2024 but slightly declined to INR 18.41 crore in March 2025. Profit before tax improved significantly from a loss of INR 3.27 crore in March 2021 to a profit of INR 6.92 crore in March 2025, while profit after tax rose from a loss of INR 2.48 crore in March 2021 to INR 5.16 crore in March 2025. The company’s total liabilities increased to INR 133.47 crore in March 2025, driven by higher short-term borrowings, while total assets also grew to INR 133.47 crore, supported by rising inventories and sundry debtors. Cash flow from operating activities remained stable, with a net cash inflow of INR 2.00 crore in March 2025, indicating improved liquidity and operational efficiency.

Why is Lactose (India) Ltd falling/rising?

As of 31-Jan, Lactose (India) Ltd's stock price is at 96.00, reflecting a decline of 1.44% and a total drop of 4.24% over the last two days. The stock has significantly underperformed over the past year, down 49.21%, while the market has gained, indicating ongoing challenges in its financial health.

As of 31-Jan, Lactose (India) Ltd's stock price is falling, currently at 96.00, which reflects a decrease of 1.4 or 1.44%. The stock has been underperforming significantly, with a consecutive decline over the last two days, resulting in a total drop of 4.24% during this period. Additionally, the stock has underperformed its sector by 2.37% today.<BR><BR>In terms of longer-term performance, Lactose (India) has shown a substantial decline of 49.21% over the past year, while the broader market, represented by the Sensex, has gained 7.18%. This stark contrast highlights the stock's weak performance relative to the market. The company's fundamentals also indicate challenges, with a low average Return on Capital Employed (ROCE) of 9.74% and a high Debt to EBITDA ratio of 3.54 times, suggesting difficulties in servicing debt.<BR><BR>Moreover, 26.07% of promoter shares are pledged, which can exert additional downward pressure on the stock price in a declining market. Despite some positive financial results reported in September, including the highest net sales and operating profit to interest ratio, the overall sentiment remains negative due to the significant drop in profits by 51.6% over the past year. Consequently, these factors contribute to the ongoing decline in Lactose (India) Ltd's stock price.

Which are the latest news on Lactose (India)?

Should I buy, sell or hold Lactose (India) Ltd?